Friday, 01 March 2019 19:48

Anticoagulation news items. Week commencing 25th February 2019

NIHR Signal: Prolonging anticoagulant treatment after abdominal cancer surgery reduces clot risk

National Institute for Health Research Signal

An expert opinion is provided of a Cochrane review which concluded that the incidence of venous thromboembolism was reduced in people who have low molecular weight heparin (LMWH) for between two to four weeks after abdominal or pelvic surgery, especially for cancer.

 

Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Cohort Study

Annals of Internal Medicine

This is an evaluation of prognostic bleeding risk models, with a view to developing a model to be used to estimate the absolute bleeding harms of aspirin among persons in whom aspirin is being considered for the primary prevention of CVD.

 

Antiplatelet Therapy vs Anticoagulation Therapy in Cervical Artery Dissection The Cervical Artery Dissection in Stroke Study (CADISS) Randomized Clinical Trial Final Results

JAMA Neurology

This RCT (n=250) reports risk of recurrent stroke at 1 year was 2.5%, with no difference in recurrence rates or rates of angiographic recanalisation with either antiplatelets or anticoagulants.

 

Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial

European Heart Journal

Pre-specified sub-group analysis (n=2725) reported that benefits of dabigatran dual therapy vs warfarin triple therapy in reducing bleeding risks were consistent across subgroups of patients with or without acute coronary syndrome, and patients treated with ticagrelor or clopidogrel.

 

Acute dual antiplatelet therapy for minor ischaemic stroke or transient ischaemic attack

British Medical Journal
BMJ analysis discusses recent evidence and recommends that dual antiplatelet therapy should be started as soon as possible within 24 hours of minor ischaemic stroke or high risk transient ischaemic attack and should be continued up to 21 days.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:

http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services